EXACT Sciences Corp. Hits New 52-Week High of $103.75

EXACT Sciences Corp. has reached a significant milestone by hitting a new 52-week high of USD 103.75 on March 9, 2026. This achievement underscores the company's strong performance in the Pharmaceuticals & Biotechnology sector, where it has demonstrated a remarkable one-year performance of 141.8%, significantly outpacing the S&P 500's 17.78% return. With a market capitalization of USD 19,744 million, EXACT Sciences operates as a mid-cap company, indicating its substantial presence in the market. Despite being loss-making, the company maintains a debt-to-equity ratio of 0.58, reflecting a manageable level of debt relative to its equity. The price-to-book ratio stands at 8.22, suggesting that investors are willing to pay a premium for the company's assets. The stock's previous 52-week low was recorded at USD 38.81, highlighting the impressive growth trajectory it has experienced over the past year. As EXACT Sciences continues to navigate the dynamic landscape of the biotechnology industry, this new high marks a notable point in its ongoing journey.